Phase 4
Completed N=30
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Source: ClinicalTrials.gov NCT02653560 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcomePrimary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg
◆ Published Evidence
Highly cited
164citations · ~10 / year
Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives.
Summary
In the DASH (Dietary Approaches to Stop Hypertension) trials, a diet rich in fruits, vegetables, nuts and dairy products, and limited in fat content, was shown to be useful in controlling hypertension. Key components of such a diet are potassium, magnesium and alkali, each of which has been implicated in lowering blood pressure. Whether a liquid formulation of potassium-magnesium citrate will result in equivalent BP effect as the DASH diet is unknown.
Linked Publications (5)
-
Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives.
-
Effect of short-term supplementation of potassium chloride and potassium citrate on blood pressure in hypertensives.
-
Food group sources of nutrients in the dietary patterns of the DASH-Sodium trial.
-
The DASH diet enhances the blood pressure response to losartan in hypertensive patients.
-
Blood pressure response during long-term treatment with magnesium is dependent on magnesium status. A double-blind, placebo-controlled study in essential hypertension and in subjects with high-normal blood pressure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY 24-hour Average Systolic Blood Pressure |
127; 127; 126; 129 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with pre- or Stage I hypertension, with systolic blood pressure of 120-159 mm and diastolic of 80-99 mm
- Age > 21 years of age
Exclusion Criteria
- Diabetes mellitus,
- Renal impairment (serum creatinine > 1.4 mg/dL),
- Any heart diseases such as congestive heart failure or sustained arrhythmia,
- Chronic NSAID use,
- Treatment with diuretics,
- Gastroesophageal reflux disease (GERD) requiring treatment with acid reducing agents or antacid more than once a week,
- Esophageal-gastric ulcer,
- Chronic diarrhea
- Hyperkalemia (serum > 4.6 mmol/L for patients on Angiotensin converting enzyme (ACE) inhibitors or Angiotensin receptor blockers (ARB), serum K > 5.0 for patient not on ACE inhibitors or ARBs)
- Liver function test above upper limit of normal range.
- Subjects who require any potassium supplement on a regular basis from any reasons
- Pregnancy
- History of major depression, bipolar disorder, or schizophrenia
- History of substance abuse.
Data sourced from ClinicalTrials.gov (NCT02653560) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.